Podcasts about ocular surface disease

Join Dr. Mile Brujic on the OI Show as he delves into the intricate world of neuropathic ocular pain with expert guest, Dr. Kaleb Abbott. As an optometrist and assistant professor at the University of Colorado School of Medicine, Dr. Abbott specializes in complex ocular surface diseases. Together, they uncover the nuances of neuropathic dry eye, a condition challenging to diagnose and treat.Key Highlights:Understanding neuropathic ocular pain: When symptoms outweigh signs.Insights into diagnostic tools like in vivo confocal microscopy and the role of proparacaine testing.Practical approaches to differentiate peripheral and central neuropathic pain.Off-label treatments, including varenicline nasal spray and its potential in trigeminal nerve modulation.Strategies for co-managing patients with neurologists and pain specialists.Dr. Abbott shares actionable tips to help eye care professionals manage these complex cases, improve patient outcomes, and explore emerging therapies.Tune in to learn cutting-edge insights into managing neuropathic pain in practice! Subscribe to the OI Show for more expert-driven episodes, and don't forget to share this episode with colleagues passionate about advancing patient care.About Kaleb Abbott Is an optometrist and assistant professor of ophthalmology at the University of Colorado School of Medicine. He is faculty in both the Dry Eye Clinic and the Center for Ocular Inflammation where he specializes in complex ocular surface disease and participates in clinical trials/research pertaining to ocular surface disease. In addition to his clinical and research duties, he is on the board of directors for the Ocular Wellness and Nutrition Society; Vice Chair of the Nutrition, Disease Prevention, and Wellness SIG for AAO; on the advisory council for the Academic Medical Center Optometry AAO SIG; and on the editorial advisory board for Optometry360. He will be graduating from the AAO Flom Leadership Academy at AAO 2024. In 2024, he became host of the Dry Eye and Ocular Surface Disease section of the Clinical Podcast Series through the American Academy of Optometry Foundation. In 2019, Kaleb co-founded a start-up company called SunSnap Kids which took 1st place in the inaugural Bright Ideas Pitch Competition in 2022 and 3rd place in the Optometry Innovation Awards in 2023. Recently he sold the majority of this company to focus more on his clinical and research responsibilities at the University of Colorado. When not seeing patients, conducting research, or working on SunSnap Kids, Dr. Abbott lectures on ocular surface disease, writes articles, and is a medical reviewer for multiple medical journals including The Ocular Surface and Optometry and Vision Science. He resides in Denver, CO with his wife, daughter, and newborn twins. 

This episode explores the fascinating connection between hormonal changes and eye health with Consultant Ophthalmologist and Ocular Surface specialist Ms. Nikolina Budimlija, who's shares her knowledge and discusses techniques like brow lifts and eyelid surgeries, and delve into the patient experience with blepharoplasty.Nikolina is a leading expert in Ocular Surface Diseases practicing at IOES Waterford and IOES Kildare and initiated Ireland's first dedicated Ocular Surface Disease clinic at the Institute of Eye Surgery. Nikolina's dedication to eye health extends beyond her clinical practice. She also spearheaded the development of a highly successful intense pulsed light service at IOES, utilising cutting-edge technology.We also answer all the questions you submitted, of which there were many! This conversation is packed with invaluable insights for anyone interested in eye health, care and beyond. Hosted on Acast. See acast.com/privacy for more information.

About Kaleb Abbott Is an optometrist and assistant professor of ophthalmology at the University of Colorado School of Medicine. He is faculty in both the Dry Eye Clinic and the Center for Ocular Inflammation where he specializes in complex ocular surface disease and participates in clinical trials/research pertaining to ocular surface disease. In addition to his clinical and research duties, he is on the board of directors for the Ocular Wellness and Nutrition Society; Vice Chair of the Nutrition, Disease Prevention, and Wellness SIG for AAO; on the advisory council for the Academic Medical Center Optometry AAO SIG; and on the editorial advisory board for Optometry360. He will be graduating from the AAO Flom Leadership Academy at AAO 2024. In 2024, he became host of the Dry Eye and Ocular Surface Disease section of the Clinical Podcast Series through the American Academy of Optometry Foundation. In 2019, Kaleb co-founded a start-up company called SunSnap Kids which took 1st place in the inaugural Bright Ideas Pitch Competition in 2022 and 3rd place in the Optometry Innovation Awards in 2023. Recently he sold the majority of this company to focus more on his clinical and research responsibilities at the University of Colorado. When not seeing patients, conducting research, or working on SunSnap Kids, Dr. Abbott lectures on ocular surface disease, writes articles, and is a medical reviewer for multiple medical journals including The Ocular Surface and Optometry and Vision Science. He resides in Denver, CO with his wife, daughter, and newborn twins. 

Dr. Cory Lappin knew as an optometry student that he found his passion for dry eye, cornea and anterior segment disease as his fellow students commonly complained about symptoms of dry eye. After completing his residency at Cincinnati Eye Institute, he was fortunate to join Phoenix Eye Care and Dry Eye Center of Arizona, where he was mentored by the legendary Dr. Art Epstein. Since publishing the Ultimate Guide to Dry Eye, Dr. Lappin has continued to pursue his passion for writing and educating, putting an emphasis on scientific literacy. Dr. Lappin's passion for the advances in ocular surface disease diagnosis and treatment is contagious. Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

Dr. Marc Odrich is Chief Medical Officer at LENZ therapeutics and has decades of experience in private practice, teaching, and medical research that contributes to LENZ Therapeutics success by driving the clinical trial and approval of our novel products. His expertise in authoring and directing over 25 clinical trials throughout his career makes him uniquely qualified to execute the approval process. In addition to his duties as Chief Medical Officer, Dr. Odrich is an Associate Professor of Ophthalmology at the University of Virginia, where he practices and teaches Clinical Ophthalmology specializing in Refractive Surgery and Ocular Surface Disease. He is also the Chief Medical Officer for TearSolutions, Inc., a startup in clinical trials for a new drug developed for dry eye disease. In addition, he is a consultant and member of the Board of Directors for CXLO, Inc., a developer of an innovative treatment for keratoconus and other corneal ectasias, as well as a consultant and medical monitor for Johnson & Johnson's refractive products. Previously, he played pivotal roles in the development and commercialization of the Excimer and Femto lasers as Medical Director at Visx. Dr. Odrich is a graduate of Columbia College and received his medical degree from Columbia University College of Physicians and Surgeons. He completed an internship in internal medicine at Yale's Danbury Hospital before moving to pursue his residency at Columbia's Harkness Eye Institute. Odrich then completed a two-year fellowship focused on cornea and external disease at Harvard's Massachusetts Eye and Ear Infirmary.

Dr Cynthia Matossian founded Matossian Eye Associates which grew into a large practice and then was transferred to an even larger ophthalmic group. An Emeritus board-certified refractive cataract surgeon, she specializes in Dry Eye and Ocular Surface Disease. She is also the CEO of GPOphtho, a group purchasing organization for ophthalmology. Dr. Matossian is also a consultant and advisor with multiple pharma and medical device companies within the eye space. She has experienced an incredible journey with ophthalmology and in this podcast she shares all of her insights. We feature a new podcast every week on Sundays and they are uploaded to all major podcast services (click links here: Apple, Google, Spotify) for enjoying as you drive to work or exercise. I am really excited to share these amazing podcasts with you. The full video of the podcast will also be here on CataractCoach as well as on our YouTube channel. Our podcast is now sponsored by Harrow, Inc and we are thankful for their support.

In this episode, Ayesha spoke with H. B. Pierre Simon Jr., MBA, Vice President, Global Head of Marketing, Sight Sciences, about the evolving field of eye care. Sight Sciences is focused on developing and commercializing innovative solutions for eye diseases like glaucoma and dry eye disease to transform care and improve patients' lives.Among some of Sight Sciences devices and technologies include the OMNI® Surgical System, a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world's leading cause of irreversible blindness. The company's other notable product is the TearCare® System, which has FDA clearance for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease.Pierre has been in the eye care industry for almost two decades. Prior to Sight Sciences, he was at Alcon for 15 years in roles with increasing responsibility, including Senior Product Manager, Global Franchise. Pierre is also a life influencer and two-time best-selling author. His latest book is entitled ‘Down Thru Love,' a story about the journey of a young man born with Down syndrome.In the episode, Pierre discusses some important considerations in the development of innovative new treatments for eye conditions like glaucoma and dry eye, such as working with patients and doctors and having an awareness of both current and future needs. Hear more about Pierre's work at Sight Sciences and also as an author and speaker. For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

About  Adele Jefferies MSc(Hons) BOptom(Hons) CertOcPharm(Therapeutics) Adele is a clinical optometrist working in independent practice in Auckland, New Zealand, with special interests in Dry Eye & Ocular Surface Disease, Myopia Management, Contact Lenses and Ocular Therapeutics. She is the National Clinical Manager for Matthews Eyecare; she holds positions on the CPD Accreditation Committee for the New Zealand Optometrists and Dispensing Opticians Board and the Health Practitioners Disciplinary Tribunal, is the President of the Cornea & Contact Lens Society (NZ), and an Honorary Teaching Fellow at the University of Auckland School of Optometry & Vision Science. She graduated from the University of Auckland in 2003 and completed her Master of Science in 2020. She has been a conference speaker for optometrists & dispensing opticians in Australia and New Zealand, a writer in optometric publications, and a pre-market evaluator of contact lenses, contact lens care solutions and dry eye care products for various companies.----Thanks to TEEM for their support of this episode. If you're considering or have ever considered getting a virtual team member for your practice check out hiredteem.com, mention The OI Show when signing up for a $250 dollar discount off of your first month's teem member.https://hireteem.com/myopia-podcast/

Office Talk: How I Am Growing My Ocular Surface Disease Clinic - E180 Highlights from this episode: Office Talk: How I Am Growing My Ocular Surface Disease Clinic (00:28) Closing Thought: Our ducks are not all in a row (09:46) In this week's office talk we are talking about growing the ocular surface disease part of the practice. We have come leaps and bounds from where we were just a year ago when we had just gotten our IPL. It's been incredible how much the entire team has learned and is continuing to learn as we become masters of our craft! Join in the fun and subscribe to the podcast to keep up with all the great content coming down the pipe! For exclusive content, be sure to register your email on our website and I will be sending out newsletters and other great bonuses as we go. I love getting feedback, questions, suggestions, etc. so contact me at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.theultimateod.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, on social media (click here for -> ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) OR, just shoot me an email at drlillie@theultimateod.com and I'd be happy to chat! --- Send in a voice message: https://podcasters.spotify.com/pod/show/theultimateodpodcast/message

Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novaliq for evaporative dry eye disease. On today's podcast, two ocular surface disease experts talk about these and other developments related to dry eye.Our guests:Laura Periman, MD, aka “the dry eye master” and founder of Periman Eye InstituteLisa Nijm, MD, JD, a corneal, cataract, and Lasik specialist at Warrenville Eyecare and Lasik in Warrenville, IllinoisDr. Periman was an investigator in the Xdemvy clinical trials, and Dr. Nijm was involved in an extended observational study.“Before Xdemvy, patients' options were limited,” Dr. Nijm told host Carey Powers. “When treated with Xdemvy, at one year, about 60 percent of patients still had clearance of Demodex.”Periman noted that during clinical trials, within a week or two she noticed “impressive improvements” in redness, reduction of collarette, and mite load in patients treated with Xdemvy. She also said the drug was “extremely well tolerated.”Miebo, a product designed to prevent excessive tear evaporation in patients with dry eye, is also expected to bring relief to a wide number of people. Dr. Periman sees Miebo as a “rapid go-to” for patients with an evaporative component, as it will potentially allow the ocular surface to protect the cornea as it's supposed to.These two products alone will help make ocular surface diseases easier to manage; however, other exciting innovations emerging later this year could liven up the playing field.Listen to the podcast today to discover:Drs. Periman and Nijm's insights into the Xdemvy clinical trias and why they're not surprised the drug received early FDA approval.How to identify Demodex in the clinic: a quick tip from Dr. Periman.Why patient education around lid hygiene remains important even with use of Xdemvy.How to best use the latest dry eye treatments to treat ocular surface disease.What makes Miebo a unique and widely applicable product.Innovations on the horizon in dry eye disease, from pharmaceuticals to neurostimulators.How the aesthetic components of dry eye disease factor into clinical care.[Listen Now]ResourcesLisa Nijm, MD, JD: warrenvilleeyecare.comLaura Periman, MD:  dryeyemaster.com/about-laura-perimanCarey Powers: ois.net/carey-powers

Join this season's expert panel of Kourtney Houser, MD; Mitch Ibach, OD; and Nandini Venkateswaran, MD, as they showcase a selection of fascinating cases across the ocular surface spectrum. 

Join this season's expert panel of Kourtney Houser, MD; Mitch Ibach, OD; and Nandini Venkateswaran, MD, as they showcase a selection of fascinating cases across the ocular surface spectrum. 

In this episode, we are joined by Dr. Anith Pillai, an expert in the field of orthokeratology, and he shares about Massive Modification of the Corneal Shape with OrthokeratologyOrthokeratology, also known as ortho-k, is a non-surgical procedure that uses specialized contact lenses to reshape the cornea and improve vision. In this episode, Dr. Pillai shares his insights on how this technique can be used to achieve significant changes in corneal shape and treat even the most complex cases of myopia.So join us for this informative and engaging episode of The Myopia Podcast, as we explore the world of orthokeratology and the innovative work of Dr. Anith Pillai. Don't miss this episode. You will surely learn a lot. About Dr. Anith Pillai:Dr. Pillai received his undergraduate degree from the University of Texas at Austin and his Doctor of Optometry from the University Of Houston College Of Optometry. He is the co-owner of Evolutionary Eye Care, where he has a clinical emphasis in anterior segment disease including Keratoconus, Specialty Contact Lenses, Orthokeratology/Myopia Management, and Ocular Surface Disease. He has writtenarticles and lectured on the topics of Scleral Lenses, Ocular Surface Disease, Orthokeratology, and Practice management. He is a Fellow of the International Academy of Orthokeratology and Myopia control and of the Scleral Lens Education Society. He is clinical adjunct professor at the University Of Houston College Of Optometry. He is an active member of the American Optometric Association and the Texas Optometric Association. He serves as the President of the Harris County Optometric Society, on the Board for the American Academy of Orthokeratology and Myopia Control, and is the Texas leader of the Young ODs of America.

Jeff Varanelli, OD, FAAO, Dipl. AAO, ABO, ABCMOFrom his early days in laser surgery to working with an ophthalmologist, Dr. Varanelli found his passion for the anterior segment to help his patients improve their overall eye health. For more than a decade, Dr. Varanelli has been an enthusiastic educator on all things related to dry eye and ocular surface disease. He is now taking the lead in Neurotrophic Keratitis (NK). Beyond herpetic eye disease, learn about other causes of NK and how to detect it, classify stages, and treat it more proactively. The doctors also discuss how they find ways to work within the system to advocate for the patient, even though insurance hurdles can be extremely frustrating for both patient and practitioner. Hosted by Joseph Allen, OD, FAAO, Diplo ABODr. Joseph Allen may be most well known as @DoctorEyeHealth on YouTube where he shares tips and education about eyes and vision for the general public.  Now, with his Eye Give a Damn! Podcast series, Dr. Allen goes in depth with his colleagues to discuss the challenges and opportunities facing optometry. From finances, private equity and insurance headaches to specialty lenses and the frontlines of scope expansion, hear from leading optometrists and industry friends. They sit down with Dr. Allen to share their personal journeys in eye care, expertise and passions. Discover why so many of us give a damn about the future of optometry and the variety of ways we can drive our industry forward! Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.

Today's podcast shines the spotlight on the front of the eye, focusing new treatments and approaches to dry eye disease, blepharitis, and Sjogren's Syndrome, to name a few.Kelly Nichols, OD, PhD, dean of the University of Alabama at Birmingham School of Optometry, guides a panel of four clinical and industry experts through a robust conversation on ocular surface disease.They start by sharing their optimism around new treatments and awareness initiatives. Jeffrey Nau, PhD, president of the newly formed Viatris Eye Care Division, said progress is inching along now, but “it's only a matter of time until we have a massive uplift that will completely change the way we look at ocular surface disease.”In late 2021, the FDA approved Tyrvaya, the first nasal spray for dry eye disease. Researchers continue to evaluate treatments and diagnostics from multiple angles. Physicians continue to tailor their approaches to better educate, diagnose, and treat ocular surface disease patients. What's next?Listen to the podcast today to hear the panelists discuss these and other topics, including:What excites you about current and emerging eye care innovations?What's your approach for both new and returning dry eye patients?What's your typical patient intake workflow?How much time do you spend educating dry eye patients?How important are companion diagnostics in ocular surface disease?[Press Play to Listen]

Today, it's all about the eyes, which are somewhat the extension of our brain, so treating ANY condition with them can be scary. I've gotten a lot of questions from listeners about dupilumab (Dupixent) and the side effects specifically when it comes to the eyes. So to dive in on this topic, I brought in today's guest, Dr. Roselie Achten, since her PhD focuses on ocular surface disease in atopic dermatitis patients before and during dupilumab treatment. Dr. Roselie Achten is a medical doctor and PhD student at the Department of Dermatology at the University Medical Center Utrecht in the Netherlands, and I am so excited to have her on the show! You can find some of her research findings in the links section below. Have you ever experienced any side effects with your eyes after starting dupilumab? I'd love to hear about it in the comments! In this episode: Stats on how many patients develop Dupixent eye side effects (aka. dupilumab-associated ocular surface disease) Eye symptoms of patients commonly complain about How long does it typically take to develop eye problems from Dupixent? What puts you more at risk for developing Dupixent eye side effects? What are your options if you develop Dupixent eye side effects? Can reducing the use of Dupixent help? Quotes “We were also quite surprised by the fact that the majority of the patients with moderate to severe atopic dermatitis already had characteristics of the ocular surface disease. So of the 70 patients that were analyzed, 90% of them already had characteristics of ocular surface disease before the start of Dupilumab treatment." [11:09] "If patients have these signs and symptoms of dupilumab associated ocular surface disease, we first start with tacrolimus skin ointment for the external eyelids. We also start with ketotifen, which is an antihistamine eye drop... also the artificial tears, it's more for if you experience a dry eye sensation, it could lead to improvement of that symptom for a little time." [17:12] Links Find Dr. Roselie Achten online here Healthy Skin Show ep. 244: How Do Biologic Drugs For Chronic Skin Conditions Work? w/ Heather Zwickey, PhD Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis - ScienceDirect Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis - PMC (nih.gov) Ocular surface disease is common in moderate to severe atopic dermatitis patients - Achten - 2022 - Clinical & Experimental Allergy

We talk about "Eyesthetics" with guest appearances from Drs. Kerry Salsberg, Jordan Friedman, Michelle Baron.  Dry Eye Hive is a  live dry eye show where "dry eye docs talk shop." Come to engage in a casual townhall style talk show every other Tuesday at 8:30pm ET. Learn from doctors in the trenches making it happen in their offices. Sponsors: Dry Eye RescueZocularEye Help You 

Episode 1 of 6 of Dry Eye Hive, the talk show for dry eye docs airing live bi-weekly Tuesdays at 8:30pm ET. It's straight Q&A with doctors in the trenches. None of the KOL stuff. It's free of sponsor pitches, regulation, and is downright informational with no slidedecks.Signup here: https://dryeyehive.com/Here's what you can expect:Focused bi-weekly topicClinical and business10-min opening monologue90 mins of Q&A with peersWebcams encouraged!No slidedecksNo KOL biasEducation from those in the trenchesSupport our sponsors: Zocular and Dry Eye Rescue and Eye Help You

Join this season's expert panel of Laura Periman, MD; Carly Rose, OD; and Edward Jaccoma, MD, as they showcase a selection of interesting cases across the ocular surface spectrum. 

Join this season's expert panel of Laura Periman, MD; Carly Rose, OD; and Edward Jaccoma, MD, as they showcase a selection of interesting cases across the ocular surface spectrum. 

The newest season includes a new expert panel featuring Jackie Garlich, OD, FAAO; Justin Schweitzer, OD, FAAO; and William B. Trattler, MD, as they share unique cases of meibomian gland dysfunction, neurotrophic keratitis, and the impact of ocular surface disease on cataract surgery planning.

The newest season includes a new expert panel featuring Jackie Garlich, OD, FAAO; Justin Schweitzer, OD, FAAO; and William B. Trattler, MD, as they share unique cases of meibomian gland dysfunction, neurotrophic keratitis, and the impact of ocular surface disease on cataract surgery planning.

Don't miss this season in which our new expert panel of Leslie O'Dell, OD, FAAO; Emilie Seitz, OD; and Ivan Mac, MD, MBA, discuss unique and challenging cases involving ocular surface disease and dry eye.

Don't miss this season in which our new expert panel of Leslie O'Dell, OD, FAAO; Emilie Seitz, OD; and Ivan Mac, MD, MBA, discuss unique and challenging cases involving ocular surface disease and dry eye.

About Dr. Joe Boorady:Joe Boorady, O.D., F.A.A.O. is a veteran in the eye care community with over 25 years of experience. He currently serves as Global CEO of Eureka Technology Holdings, LTD  and Euclid Systems Corporation.  Prior to Eureka, Dr. Boorady was the VP, Ocular Surface Disease at Johnson and Johnson Vision. Prior to Johnson and Johnson Vision he was the President and CEO of TearScience, Inc. which was acquired by Johnson and Johnson Vision in Sept. 2017. Before joining TearScience, Dr. Boorady was Senior Vice President of Sales, Service and Marketing at Zeiss Meditec, Inc. Dr. Boorady has spent over 25 years in the ophthalmic industry as an eye care professional, educational leader, entrepreneur and corporate executive. He has clinical experience as the founder and owner of several primary eye care practices in New York and New Jersey. He was the Vice President for Clinic Affairs and Executive Director of the University Optometric Center of the SUNY College of Optometry in New York City. Prior to his most recent position at SUNY, Dr. Boorady was Director of Continuing Professional Education, delivering eye care education to optometrists and ophthalmologists in over 20 countries, Director of Managed Care for eight years, Founding Director of the University Eye Care Network, IPA. Dr. Boorady has an O.D. from the SUNY-College of Optometry Class of 1993 and in 2010 he became an alumnus of the Harvard Business School. 

Join this season's new expert panel of Cecelia Koetting, OD; Walt Whitley, OD; and Marjan Farid, MD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

Join this season's new expert panel of Cecelia Koetting, OD; Walt Whitley, OD; and Marjan Farid, MD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

In this episode of To the Point, Jackie Garlich, OD, FAAO, and Leslie O'Dell, OD, FAAO, are joined by Kambiz Silani, OD, Chief Clinical Director of Beverly Hills Optometry and founder of its Advanced Dry Eye Center. Dr. Silani elaborates on how his high-tech practice utilizes office-based devices to properly diagnose and treat patients with ocular surface disease. He also discusses his path to dry eye, his use of social media to grow his practice, and more.

Managing Ocular Surface Disease in Special Patient Populations

Chris Starr, MD leads a new expert panel of Preeya Gupta, MD; Douglas DeVries, OD; and Leslie O'Dell, OD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

Chris Starr, MD leads a new expert panel of Preeya Gupta, MD; Douglas DeVries, OD; and Leslie O'Dell, OD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

Join our expert panel of Ivan Mac, MD; Damon Dierker, OD; and Brandon Ayres, MD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

Join our expert panel of Ivan Mac, MD; Damon Dierker, OD; and Brandon Ayres, MD, as they deliberate on a myriad of interesting cases across the ocular surface spectrum. 

Eric Brooker, OD, FAAO, and Lisa Feulner, MD, PhD, join Marguerite McDonald, MD, FACS, to discuss their approaches to the education and treatment of patients with advanced ocular surface disease.

Eric Brooker, OD, FAAO, and Lisa Feulner, MD, PhD, join Marguerite McDonald, MD, FACS, to discuss their approaches to the education and treatment of patients with advanced ocular surface disease.

In this episode of the OIS Podcast we are sharing more “best-of” content from the recent OIS@SECO. Summit Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH, engages vision industry Titans in a discussion around their latest innovations for both the Ophthalmic and Optometric markets.Participants:Glen Curran, VP, Anterior Segment Marketing, US Eye Care - AllerganJohn Ferris, VP & General Manager, Vision Care - Bausch + LombKurt Moody, OD, FAAO, Director, Ocular Surface Disease & Professional Strategy - Johnson & Johnson VisionAndy Pawson, President & GM, Global Vision Care - AlconPaul Smith, VP, Business Unit Head, Eye Care - NovartisModerated By:Emmett T. Cunningham Jr., MD, PhD, MPH, Senior Managing Director - Blackstone Life SciencesMore on OIS@SECO 2020:https://ois.net/ois-seco-2020

In this special episode of the OIS podcast, we have a discussion that took place during the recent OIS@SECO in Atlanta. Summit Co-Chairman, Paul Karpecki, OD, FFAO, set the stage with some staggering figures which led to an insightful conversation between two ODs and two MDs about Collaborative Care models and the benefits to both patients and practices.Participants:Thomas Chester, OD, Clinical Director - Cleveland Eye ClinicElise Kramer, OD, FAAO - Miami Contact Lens InstituteWilliam Trattler, MD, Director of Cornea - Center For Excellence In EyecareWilliam Wiley, MD - Cleveland Eye ClinicModerated By:Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye InstituteMore on OIS@SECO 2020:https://ois.net/ois-seco-2020

Happy New Year Everyone! We're kicking off 2020 (the year of Ophthalmology and Optometry) with a star-studded episode for you! We are diving deep into Ocular Surface Disease with the jedi masters of dry eye! Guests: Patti Barkey, COE. (3:11) CEO of Bowden Eye and Director of Dry Eye University. Dr. Adam Ramsey, OD. (23:30) CEO of Socialite Vision and Author of Play Chess, Not Checkers. Dr. Laura Periman, MD. (48:11) Ocular Surface Disease Expert and Dry Eye Master. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/bigeyedeas/message

In this episode of Eyetrepreneur, Dr. Richard Maharaj discusses the different specialties surrounding optometry, the psychology surrounding optometry from both the doctor and patient perspective, and so much more. Enjoy! In This Episode: [3:09] Dr. Maharaj's journey into eyecare and where he is today. [9:40] Why are specialties in optometry emerging right now? [16:48] The experience of seeing an eye doctor. [19:50] Should you get rid of retail? [22:20] How hard should you look into the wallets of your patients? [37:48] How Canada helps those patients who can't work and afford care. [39:58] Collaborative eyecare in Canada. [49:15] Handling patients that are having trouble understanding their condition. [59:09] How to maintain pricing even when competitors lower their pricing. About The Guest: Dr. Richard Maharaj is the current medical director for eyeLABS Center for Ocular Surface Disease a leading specialty eye Care and research facility outside of Toronto. He obtained his Doctor of Optometry from the University of Waterloo School of Optometry and is an active Fellow of the American Academy of Optometry.   He is a clinical adjunct faculty for the University of Waterloo School of Optometry, the Canadian Association of Optometrists Section Chair for Ocular Surface Disease, Editorial Board Member for The Journal of Dry Eye and Ocular Surface Disease, and Chief Education Officer at MyDryEye.ca and co-founder for the Canadian Dry Eye Summit - a national conference dedicated to educating eye doctors in the area of dry eye disease management.  He is a published respected national speaker and clinical scientist on diseases of the ocular surface. He was honored as one of the Top 40 Canadian Optometrists under 40 by Johnson and Johnson Vision Care in 2018 Important Links: EyeLabs.ca

Q4: How do you identify OSD in patients, and what measures are required before proceeding with surgery?   From the Marco Power Forum III, New Orleans, LA  with: Larry Patterson, MD Mitch Jackson, MD Cynthia Matossian, MD Neda Shamie, MD Toby Tyson, MD   For more visit https://marco.com/

Caroline Blackie is an internationally recognized clinical and scientific expert in the field of dry eye with specific focus on meibomian gland dysfunction. She has authored and published over 40 scientific articles in this area. She currently serves as the Medical Director for Ocular Surface Disease for Johnson and Johnson Vision, providing medical and scientific leadership to drive and shape innovation in this therapeutic area.  Dr. Blackie joined Johnson and Johnson Vision after 12 years with TearScience. At TearScience, she served on the small team of individuals who imagined, designed, developed, tested, and brought to market all of the TearScience Products. Passionate about the patient experience, she also successfully divided her time between clinical research and development and private practice, accruing approximately 20 years of direct patient care experience in her career.  Her years in direct clinical care, fuel her desire to elevate and transform the standard of care towards a more proactive approach to ocular surface health. Brian Regan is a growth, launch and turnaround sales and marketing executive with history delivering innovation for patient care, revenue growth and significant investor value. Skilled in leadership of sales and marketing, business strategy, market research, KOL development, customer service, CRM, and metrics reflecting progress on KPI’s. 

2 interviews this week.   In the first interview, Sean Henahan talks to José Güell, Associate Professor Ophthalmology, Autonoma University, Barcelona, Spain, about Ocular Surface Disease and the impact it has on surgical outcomes.   In the second interview,Paul Rosen interviews Penny Asbell who says point-of-care testing may help ophthalmologists  move forward to a more  patient-centred approach in the diagnosis of Dry Eye Disease.

Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia

Guest: Dr Laura Downie, PhD Senior Lecturer, NHMRC Translating Research Into Practice (TRIP) Fellow University of Melbourne Melbourne , Australia

Gary Wörtz, MD, sits down with Sumitra Khandelwal, MD, to talk about posterior corneal measurements for toric IOLs and the most accurate tools for acquiring information. Dr. Wörtz also speaks with John Berdahl, MD, regarding astigmatismfix.com, a tool to help surgeons correct residual astigmatism caused by common measurement deviations.

Gary Wörtz, MD, sits down with Sumitra Khandelwal, MD, to talk about posterior corneal measurements for toric IOLs and the most accurate tools for acquiring information. Dr. Wörtz also speaks with John Berdahl, MD, regarding astigmatismfix.com, a tool to help surgeons correct residual astigmatism caused by common measurement deviations.